Brief: Xintela Publishes Results From Glioblastoma Antibody Study

Xintela AB

12/03/2021 14:33

March 12 (Reuters) - Xintela AB  XINT.ST :
    * XINTELA PUBLISHES RESULTS FROM GLIOBLASTOMA ANTIBODY STUDY
    * PUBLICATION SHOWS THAT ANTIBODIES DIRECTED TO COMPANY'S
TARGET
MOLECULE INTEGRIN 101 SIGNIFICANTLY REDUCE GROWTH OF AGGRESSIVE
AND DEADLY BRAIN TUMOR GLIOBLASTOMA IN AN ANIMAL MODEL
    * RESULTS SHOW THAT XINTELA'S TARGETING ANTIBODIES ARE A
PROMISING
NEW STRATEGY FOR TREATMENT OF GLIOBLASTOMA

Source text for Eikon:  ID:nBQN2TrTJR 
Further company coverage:  XINT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))